Objective: Rosiglitazone, a thiazolidinedione compound with peroxisome proliferator-activated receptor-γ (PPAR-γ -binding affinity, is able to suppress adrenocorticotropic hormone (ACTH) secretion in treated mice and in AtT20 pituitary tumor cells. These observations suggested that thiazolidinediones may be effective as therapy for Cushing's disease (CD). Patients and methods: Rosiglitazone (8 mg/day) was administered to 14 patients with active CD (13 women, one man, 18-68 years). Plasma ACTH, serum cortisol (F) and urinary free cortisol (UFC) levels were measured before and then monthly during rosiglitazone administration. Results: In six patients a reduction of ACTH and F levels and a normalization of UFC were observed 30-60 days after the beginning of rosiglitazone administration: there was a significant difference between basal and post-treatment values for UFC (1238±211 vs 154± 40 nmol/24 h, P < 0.03), but not for ACTH (15.9±3.7 vs 7.9±0.9 pmol/l) and F levels (531±73 vs 344±58 nmol/l). Two of six cases, followed up for 7 months, showed a mild clinical improvement. Eight patients were nonresponders after 30-60 days of rosiglitazone treatment: their ACTH, F and UFC levels did not differ before and during drug administration. Immunohistochemical analysis of pituitary tumors removed from two responder and two nonresponder patients showed a similar intense immunoreactivity for PPAR-γ in about 50% of cells. Conclusions: The administration of rosiglitazone seems able to normalize cortisol secretion in some patients with CD, at least for short periods. Whether the activation of PPAR-γ by rosiglitazone might be effective as chronic pharmacologic treatment of CD needs a more extensive investigation through a randomized and controlled study.

Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease / B. Ambrosi, C. Dall'Asta, S. Cannavò, R. Libè, T. Vigo, P. Epaminonda, I. Chiodini, S. Ferrero, F. Trimarchi, M. Arosio, P. Beck-Peccoz. - In: EUROPEAN JOURNAL OF ENDOCRINOLOGY. - ISSN 0804-4643. - 151:2(2004 Aug 02), pp. 173-178. [10.1530/eje.0.1510173]

Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease

B. Ambrosi;C. Dall'Asta;I. Chiodini;S. Ferrero;M. Arosio;P. Beck-Peccoz
2004-08-02

Abstract

Objective: Rosiglitazone, a thiazolidinedione compound with peroxisome proliferator-activated receptor-γ (PPAR-γ -binding affinity, is able to suppress adrenocorticotropic hormone (ACTH) secretion in treated mice and in AtT20 pituitary tumor cells. These observations suggested that thiazolidinediones may be effective as therapy for Cushing's disease (CD). Patients and methods: Rosiglitazone (8 mg/day) was administered to 14 patients with active CD (13 women, one man, 18-68 years). Plasma ACTH, serum cortisol (F) and urinary free cortisol (UFC) levels were measured before and then monthly during rosiglitazone administration. Results: In six patients a reduction of ACTH and F levels and a normalization of UFC were observed 30-60 days after the beginning of rosiglitazone administration: there was a significant difference between basal and post-treatment values for UFC (1238±211 vs 154± 40 nmol/24 h, P < 0.03), but not for ACTH (15.9±3.7 vs 7.9±0.9 pmol/l) and F levels (531±73 vs 344±58 nmol/l). Two of six cases, followed up for 7 months, showed a mild clinical improvement. Eight patients were nonresponders after 30-60 days of rosiglitazone treatment: their ACTH, F and UFC levels did not differ before and during drug administration. Immunohistochemical analysis of pituitary tumors removed from two responder and two nonresponder patients showed a similar intense immunoreactivity for PPAR-γ in about 50% of cells. Conclusions: The administration of rosiglitazone seems able to normalize cortisol secretion in some patients with CD, at least for short periods. Whether the activation of PPAR-γ by rosiglitazone might be effective as chronic pharmacologic treatment of CD needs a more extensive investigation through a randomized and controlled study.
Settore MED/13 - Endocrinologia
Settore MED/08 - Anatomia Patologica
Article (author)
File in questo prodotto:
File Dimensione Formato  
173.full.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 240.57 kB
Formato Adobe PDF
240.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/20119
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 115
  • ???jsp.display-item.citation.isi??? 107
social impact